Prequel

The Center Welcomes CYKLAR by Claudia Sulewski to Its Distinguished Portfolio of Beauty Brands

Retrieved on: 
Thursday, March 21, 2024
MAKE, Cream, Prequel, Partnership, Beauty, Attention, Multimedia, Family, Crescent, Online shopping

Claudia Sulewski, the visionary behind CYKLAR, embarked on her entrepreneurial journey with a clear mission and a self-funded business model.

Key Points: 
  • Claudia Sulewski, the visionary behind CYKLAR, embarked on her entrepreneurial journey with a clear mission and a self-funded business model.
  • With an ambition to scale and evolve her brand, Claudia sought a partnership with a brand accelerator that shared her passion for beauty and innovation.
  • Her admiration for The Center's brands, especially MAKE Beauty, along with mutual industry contacts, facilitated a serendipitous introduction to Ben Bennett.
  • Ben Bennett, founder of The Center, shared his enthusiasm for the new addition, saying, "We are thrilled to welcome Claudia Sulewski and CYKLAR to our portfolio.

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

Retrieved on: 
Monday, November 20, 2023
Genetics, Myriad Genetics, Learning, MYGN, Patient, Pregnancy, Medicine, Genetic testing, Genomics, Blood, Parent, Myriad, Sample, Prequel, Birth control

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test .

Key Points: 
  • SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test .
  • SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby’s predicted fetal sex.
  • Samples are mailed to the SneakPeek laboratory and test results are shared as early as the same day the sample is received through email.
  • “This momentous occasion represents an exciting step forward in expanding access to fetal sex testing at six weeks,” said Melissa Gonzales, president of women’s health, Myriad Genetics.

DR. SAMANTHA ELLIS LAUNCHES SOLUTION-FOCUSED SKINCARE BRAND PREQUEL

Retrieved on: 
Tuesday, July 25, 2023
Nicotinamide, The Center, Urea, Face, Acne, Social media, Milk, Patient, Petroleum, Hearing, Irritation, Hyperpigmentation, Dry, Inulin, Skin, Cosmetics, Prequel

LOS ANGELES, July 25, 2023 /PRNewswire/ -- Dr. Samantha Ellis is thrilled to announce today the launch of Prequel, her dermatologist-developed, solution-focused skincare brand, in collaboration with The Center, a Los Angeles based brand accelerator. The brand debuts with three core products specifically designed to address skin health and the root cause of skin concerns while delivering clinical solutions to help reverse barrier dysfunction and treat skin issues, head-to-toe.

Key Points: 
  • LOS ANGELES, July 25, 2023 /PRNewswire/ -- Dr. Samantha Ellis is thrilled to announce today the launch of Prequel, her dermatologist-developed, solution-focused skincare brand, in collaboration with The Center, a Los Angeles based brand accelerator.
  • Offering a balance between doctor office brands, prescription based topicals, and over-the-counter basics, Prequel provides effective and cosmetically elegant formulas accessible to everyone.
  • "As a practicing dermatologist, after years of hearing directly from my patients what they want and need from their skincare - I've turned that into Prequel.
  • I like to think of this brand as 'basic plus' - we've taken tried and true skincare ingredients and formats, but elevated them from a formulation standpoint, a packaging standpoint and an innovation standpoint, all at an attainable price point," says Dr. Samantha Ellis.

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Retrieved on: 
Thursday, January 5, 2023
American College, Precision medicine, Medical genetics, ACMG, American College of Medical Genetics and Genomics, SALT, PPV, Myriad Genetics, DiGeorge syndrome, SCAS, Genetic testing, Prequel, MYGN, Chromosome, Patient, Guideline, Physician, Genetics, NIPS, Fetus, Association for Molecular Pathology v. Myriad Genetics, Inc., Genetic distance, Trisomy, Medical imaging, Genomics

Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.

Key Points: 
  • Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.
  • FirstGene is a 4-in-1 offering that includes NIPS for chromosomal abnormalities, carrier screening for recessive conditions, simultaneous single-gene assessment of whether the fetus is affected with a condition identified via carrier screening, and feto-maternal blood compatibility.
  • “We’re excited to introduce our FirstGene product in Q3 2023,” said Melissa Gonzales, President, Women’s Health, Myriad Genetics.
  • We are very encouraged to see that initial data supports our view that Prequel provides exemplary PPV for 22q screening via NIPS.”

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Retrieved on: 
Friday, December 9, 2022
Breast cancer, PRS, Woman, Genetic testing, Physician, Sumathi Best Television Current Reporting Award, Health, Genetics, SALT, Myriad, Myriad Genetics, Risk, Stanford University, Prequel, MYGN, HIV disease progression rates, Risk assessment, Precision medicine, Dietary supplement, Medical imaging

Working with industry-leading researchers, Myriad Genetics studied outcomes from more than 130,000 women who received RiskScore results.

Key Points: 
  • Working with industry-leading researchers, Myriad Genetics studied outcomes from more than 130,000 women who received RiskScore results.
  • By analyzing data on whether women developed breast cancer after their initial test result, the study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than a standard of care risk assessment method.
  • RiskScore is the first breast cancer risk prediction model that combines Tyrer-Cuzick with a polygenic risk score (PRS) validated for women of all ancestries.
  • This longitudinal patient outcomes study highlights RiskScore as a valuable precision medicine tool for predicting breast cancer risk,” said Thomas Slavin, M.D., Chief Medical Officer, Myriad Genetics.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Retrieved on: 
Tuesday, November 29, 2022
BRCA, Genomics, Health, Risk, CST, MYGN, Precision medicine, Recurrence, SALT, Myriad Genetics, Genetics, Patient, Myriad, Sumathi Best Television Current Reporting Award, Association for Molecular Pathology v. Myriad Genetics, Inc., Technical University of Munich, BRCA1, FDA, BRCA2, Diagnosis, Physician, Berlin, Prequel, Risk assessment, News, Genetic testing, HRD, Breast cancer, PRS, Institute of technology, University, Cancer, Woman, HIV disease progression rates, Birth control, Pharmaceutical industry, Medical imaging

SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.

Key Points: 
  • SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
  • The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer.
  • Among the Myriad products highlighted in the companys SABCS exhibit are:
    MyRisk with RiskScore , Myriads market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries.
  • RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk.

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Retrieved on: 
Thursday, November 17, 2022
Mental health, Good clinical laboratory practice, SALT, PCP, Myriad Genetics, Health, ADHD, Risk, Physician, Patient, Practitioner, Genetics, Electric Bond and Share Company v. Securities and Exchange Commission, Myriad, Prequel, Sumathi Best Television Current Reporting Award, Anxiety, Depression, NPS, HIV disease progression rates, Genetic testing, Precision medicine, Quality of life, MYGN, FDA, Medicine, Pharmaceutical industry

More than six in 10 (63%) PCPs/NPs have increased referrals to mental health specialists over the past two years, despite the shortage in available care.

Key Points: 
  • More than six in 10 (63%) PCPs/NPs have increased referrals to mental health specialists over the past two years, despite the shortage in available care.
  • According to the GeneSight Mental Health Monitor, only 18% of responding prescribers in primary care use an available tool like pharmacogenomic testing to help inform their mental health medication treatment plan.
  • Pharmacogenomic (PGx) testing, such as the GeneSight Psychotropic test, may help PCPs manage their patients mental health.
  • The GeneSight Mental Health Monitor is a nationwide survey of primary care physicians and nurse practitioners conducted online by ACUPOLL Precision Research, Inc. from August 16 - 30, 2022.

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Retrieved on: 
Monday, November 14, 2022
CNV, MYGN, LCGC, Cancer, Myriad Genetics, Sumathi Best Television Current Reporting Award, Risk, Health, CGC, Body mass index, Prenatal care, DNA, Chromosome, ASCP, HIV disease progression rates, Physician, Pregnancy, Emory University, Risk assessment, Genetic counseling, MS, Senior counsel, NSGC, JCO, Genetics, Myriad, TommyInnit, Breast cancer, Prequel, ESG, Cleveland Clinic, Precision medicine, Woman, CEU, Association for Molecular Pathology v. Myriad Genetics, Inc., SALT, Genetic testing, Patient, Genome, Agriculture, Pharmaceutical industry, Management, Medical imaging, NIPS

Were committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.

Key Points: 
  • Were committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.
  • Data will highlight how technological improvements now allow for the detection of copy number variants (CNVs) across the genome in NIPS.
  • Myriad Genetics will sponsor NSGCs welcome reception for all genetic counselors who are first-time conference attendees, Wednesday, Nov. 16, 6:00-7:00 p.m. CT.
  • Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

Retrieved on: 
Thursday, November 10, 2022
Genetics, GLOBE, Fast Company, Myriad Genetics, Private Securities Litigation Reform Act, Genetic testing, Health, Prostate cancer, SALT, Risk, Research, Adoption, Myriad, Prequel, Precision medicine, NASDAQ, HIV disease progression rates, Solution, U.S. Securities and Exchange Commission, Gene expression, HRD, Sumathi Best Television Current Reporting Award, MYGN, Biomarker, FACS, Clinical trial, Gaps, Surgery, Patient, CEO, GenesisCare, Association for Molecular Pathology v. Myriad Genetics, Inc., Medical imaging, Pharmaceutical industry

UroSuite includes Myriads Prolaris Prostate Cancer Test , MyRisk Hereditary Cancer Test, BRACAnalysis CDx and Precise Tumor Molecular Profile Test .

Key Points: 
  • UroSuite includes Myriads Prolaris Prostate Cancer Test , MyRisk Hereditary Cancer Test, BRACAnalysis CDx and Precise Tumor Molecular Profile Test .
  • The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients.
  • For more information about UroSuite and Myriad Genetics other prostate cancer care offerings, visit: https://prolaris.com/UroSuite-LUGPA.
  • Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Retrieved on: 
Thursday, November 3, 2022
Precision medicine, Genetic testing, Private Securities Litigation Reform Act, Sumathi Best Television Current Reporting Award, SALT, Myriad Genetics, Risk, Genetics, Healthcare disparity in Massachusetts, GLOBE, Woman, Cleveland Clinic, JCO, Health, Prequel, Association for Molecular Pathology v. Myriad Genetics, Inc., Fast Company, Risk assessment, HIV disease progression rates, Myriad, Physician, U.S. Securities and Exchange Commission, NASDAQ, PRS, Breast cancer, MD, MYGN, Dietary supplement, Medical imaging, Birth control

The study -- first presented in an oral presentation at the 2021 ASCO Annual Meeting by Dr. Peterson – examined data from more than 275,000 women of diverse ancestral backgrounds to validate a novel method for assessing breast cancer PRS by using ancestry-informative genetic markers.

Key Points: 
  • Our new methodology provides a framework for a recalibrated PRS that delivers a personalized genomic breast cancer risk assessment to all women.
  • RiskScore is the first risk prediction model that combines a PRS validated for women of all ancestries with clinical and biological variables.
  • It provides a five-year and lifetime risk assessment of developing breast cancer for women who qualify for MyRisk.
  • More women will be able to benefit from knowing their genomically informed risk of developing breast cancer and work with their physicians on how to best manage that risk.